← Eichor
Condition: Advanced Adenocarcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metasta
Phase 2 · 2 location(s) · Medical University of South Carolina · NCT07076212Promoting Response to IMmunotherapy by Exercise in Patients With Advanced Renal Cell Carcinoma
NA · 2 location(s) · Radboud University Medical Center · NCT07680556Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07448142Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Tr
Phase 2 · 1 location(s) · Dai, Guanghai · NCT07392346A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05672524Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma
Phase 2 · 1 location(s) · Qingdao Central Hospital · NCT04974866Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients Wi
Phase 2/Phase 3 · 10 location(s) · Beijing Biostar Pharmaceuticals Co., Ltd. · NCT06841679A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves T
Phase 1 · 11 location(s) · AbbVie · NCT06487559Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Hist
Phase 2 · 4 location(s) · Emory University · NCT05756569Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Phase 1 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT04703101Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1/Phase 2 · 18 location(s) · AstraZeneca · NCT06921928Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Phase 3 · 11 location(s) · Polaris Group · NCT05317819Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06940518Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-posit
Phase N/A · 36 location(s) · Daiichi Sankyo · NCT06846996[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
Phase 2/Phase 3 · 10 location(s) · Leiden University Medical Center · NCT07018661Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies
Phase N/A · 1 location(s) · Zhongda Hospital · NCT06607120A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 · 34 location(s) · Incyte Corporation · NCT06179160Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarc
Phase N/A · 12 location(s) · Medical University of Graz · NCT05526443NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06405490HAIC Compared With TACE in Huge Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06641713Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
Phase N/A · 1 location(s) · Centro de Tratamiento e Investigación sobre Cáncer, Luis Car · NCT07633626Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05170503A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Akeso · NCT04982276A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemothera
Phase 2 · 1 location(s) · Shandong Provincial Hospital · NCT06829797Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Wi
Phase 3 · 274 location(s) · SWOG Cancer Research Network · NCT06998940Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase II
Phase 3 · 1 location(s) · Fujian Cancer Hospital · NCT06793917A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06415669Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07026149Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
NA · 1 location(s) · Tanta University · NCT06961526
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.